Guillain-Barré syndrome in a patient with multiple myeloma after bortezomib therapy: A case report

BACKGROUND: Bortezomib is a first-line drug approved for patients with multiple myeloma (MM) and has significantly increased their overall survival. However, bortezomib-induced peripheral neuropathy (PN) remains a significant side effect that has led to its discontinuation in some patients. Guillain...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yu-Ling, Zhao, Wei-Hua, Tang, Zhong-Yuan, Li, Zhong-Qing, Long, Yuan, Cheng, Peng, Luo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789385/
https://www.ncbi.nlm.nih.gov/pubmed/31616710
http://dx.doi.org/10.12998/wjcc.v7.i18.2905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789385/
https://www.ncbi.nlm.nih.gov/pubmed/31616710
http://dx.doi.org/10.12998/wjcc.v7.i18.2905

Ejemplares similares